Q2 results: Dr Reddy’s profit surges 70%1 min read . Updated: 26 Oct 2018, 03:46 PM IST
Net profit rose to ₹518 crore in the quarter ended 30 September, from ₹305 crore a year earlier
Bengaluru: Dr Reddy’s Laboratories posted a 69.7% jump in second-quarter profit on Friday, helped by new product launches.
Net profit rose to ₹ 518 crore in the quarter ended 30 September, from ₹ 305 crore a year earlier, the company said.
That handily beat analysts’ expectations of ₹ 352 crore, according to Refinitiv data.
Net sales rose 5.6% to ₹ 3,687 crore.
Dr Reddy’s Laboratories (DRL) last week said it will sell its active pharmaceutical ingredient (API) business unit in Hyderabad to generics pharmaceutical company Therapiva Private Ltd.
Therapiva is a joint venture between Omnicare Drugs India, a wholly owned subsidiary of Neopharma LLC, Abu Dhabi and Laxai Life Sciences. The sale includes all related fixed assets (land and building), current assets, current liabilities, and its employees, the company said.
This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.